Riccardo Schiavina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Riccardo Schiavina has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Michelangelo Fiorentino
Pathology Unit IRCCS Azienda Ospedaliero‐Universitaria di Bologna Bologna Italy
8 shared publications - Lorenzo Bianchi
Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy -
6 shared publications Eugenio Brunocilla
Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
5 shared publications- Francesca Giunchi
Department of Pathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
5 shared publications - Francesco Massari
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
5 shared publications - Rita Golfieri
IRCCS Azienda Ospedaliero-Universitaria di Bologna
5 shared publications
Latest Publications
- Open Access
- 21 January 2026
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 72 (10) , e321-e324
Inferior Vena Cava Resection Using Modified Veno-Venous Bypass With Renal Vein Drainage: Case Report Adapted From Liver Transplant Practice
We describe an innovative application of a modified three-arm veno-venous bypass (VVB) in the management of a complex case of recurrent renal cell carcinoma (RCC) invading the inferior vena cava (IVC) and left renal vein confluence. The patient, with a solitary kidney following right nephrectomy, underwent radical tumor resection and IVC reconstruction. To preserve renal function and minimize ischemic injury, we employed an extracorporeal circuit traditionally used in liver transplantation, adapting it to include an additional cannula in the left renal vein. This configuration allowed continuous renal venous drainage during IVC clamping, limiting kidney warm ischemia to only 14 minutes. The extracorporeal circuit included jugular and femoral venous drainage limbs connected to a centrifugal pump and a third limb providing direct renal outflow, effectively maintaining hemodynamic stability and renal perfusion. Postoperative recovery was uneventful, with transient minimal creatinine elevation and no acute kidney injury. This case demonstrates the versatility of extracorporeal venous bypass circuits in complex onco-vascular surgery and highlights the potential for broader applications of organ support technologies in preserving organ function during major vascular reconstruction. The proposed configuration represents a valuable adjunct in surgeries involving solitary kidneys and prolonged caval occlusion, bridging concepts from transplant and extracorporeal support domains.
- 21 January 2026
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 72 (10) , e321-e324
Open AccessInferior Vena Cava Resection Using Modified Veno-Venous Bypass With Renal Vein Drainage: Case Report Adapted From Liver Transplant Practice
We describe an innovative application of a modified three-arm veno-venous bypass (VVB) in the management of a complex case of recurrent renal cell carcinoma (RCC) invading the inferior vena cava (IVC) and left renal vein confluence. The patient, with a solitary kidney following right nephrectomy, underwent radical tumor resection and IVC reconstruction. To preserve renal function and minimize ischemic injury, we employed an extracorporeal circuit traditionally used in liver transplantation, adapting it to include an additional cannula in the left renal vein. This configuration allowed continuous renal venous drainage during IVC clamping, limiting kidney warm ischemia to only 14 minutes. The extracorporeal circuit included jugular and femoral venous drainage limbs connected to a centrifugal pump and a third limb providing direct renal outflow, effectively maintaining hemodynamic stability and renal perfusion. Postoperative recovery was uneventful, with transient minimal creatinine elevation and no acute kidney injury. This case demonstrates the versatility of extracorporeal venous bypass circuits in complex onco-vascular surgery and highlights the potential for broader applications of organ support technologies in preserving organ function during major vascular reconstruction. The proposed configuration represents a valuable adjunct in surgeries involving solitary kidneys and prolonged caval occlusion, bridging concepts from transplant and extracorporeal support domains.
- Open Access
- 17 October 2023
- Published by Springer Nature in Virchows Archiv
- Vol. 483 (5) , 687-698
Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT
The 2022 WHO classification of urinary and male genital tumors introduced several novel kidney entities exhibiting eosinophilic/oncocytic features with specific mutational backgrounds. Thus, molecular techniques, such as next-generation sequencing (NGS), became more commonly used for their evaluation. We studied 12 low-grade oncocytic tumors (LOT) of the kidney (from 11 patients), identified in a cohort of 210 eosinophilic/oncocytic renal tumors, diagnosed in our institution between October 2019 and May 2023, which represented 5.7% (12/210) of all eosinophilic/oncocytic renal tumors during this period. We reviewed their clinicopathologic, histologic, and immunohistochemical features, as well as their mutational profiles. We also reviewed the literature on NGS-derived data of LOT, by selecting papers in which LOT diagnosis was rendered according to the criteria proposed initially. Median age was 65 years (mean: 63.5; range 43–79) and median tumor size was 2.0 cm (mean: 2.2; range: 0.9–3.1). All tumors were positive for PAX8, CK7, and GATA3, and negative or focally positive for CD117/KIT. We found the following gene mutations: MTOR ((6/11), 54.5%)), TSC1 ((2/11), 18.2%)), and 1 had both NOTCH1 and NOTCH4 ((1/11), 9.1%)). Wild-type status was found in 2/11 (18.2%) patients and one tumor was not analyzable. A review of 8 previous studies that included 79 LOTs revealed frequent mutations in the genes that regulate the mammalian target of rapamycin (mTOR) pathway: MTOR (32/79 (40.5%)), TSC1 (21/79 (26.6%)), and TSC2 (9/79 (11.4%)). Other mutated genes included PIK3CA, NF2, and PTEN, not typically known to affect the mTOR pathway, but potentially acting as upstream and downstream effectors. Our study shows that LOT is increasingly diagnosed in routine practice when applying the appropriate diagnostic criteria. We also confirm that the mTOR pathway is strongly implicated in the pathogenesis of this tumor mainly through MTOR, TCS1, and TSC2 mutations, but other genes could also be involved in the pathway activation, especially in LOTs without “canonical” mutations.
- 17 October 2023
- Published by Springer Nature in Virchows Archiv
- Vol. 483 (5) , 687-698
Open AccessEvaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT
The 2022 WHO classification of urinary and male genital tumors introduced several novel kidney entities exhibiting eosinophilic/oncocytic features with specific mutational backgrounds. Thus, molecular techniques, such as next-generation sequencing (NGS), became more commonly used for their evaluation. We studied 12 low-grade oncocytic tumors (LOT) of the kidney (from 11 patients), identified in a cohort of 210 eosinophilic/oncocytic renal tumors, diagnosed in our institution between October 2019 and May 2023, which represented 5.7% (12/210) of all eosinophilic/oncocytic renal tumors during this period. We reviewed their clinicopathologic, histologic, and immunohistochemical features, as well as their mutational profiles. We also reviewed the literature on NGS-derived data of LOT, by selecting papers in which LOT diagnosis was rendered according to the criteria proposed initially. Median age was 65 years (mean: 63.5; range 43–79) and median tumor size was 2.0 cm (mean: 2.2; range: 0.9–3.1). All tumors were positive for PAX8, CK7, and GATA3, and negative or focally positive for CD117/KIT. We found the following gene mutations: MTOR ((6/11), 54.5%)), TSC1 ((2/11), 18.2%)), and 1 had both NOTCH1 and NOTCH4 ((1/11), 9.1%)). Wild-type status was found in 2/11 (18.2%) patients and one tumor was not analyzable. A review of 8 previous studies that included 79 LOTs revealed frequent mutations in the genes that regulate the mammalian target of rapamycin (mTOR) pathway: MTOR (32/79 (40.5%)), TSC1 (21/79 (26.6%)), and TSC2 (9/79 (11.4%)). Other mutated genes included PIK3CA, NF2, and PTEN, not typically known to affect the mTOR pathway, but potentially acting as upstream and downstream effectors. Our study shows that LOT is increasingly diagnosed in routine practice when applying the appropriate diagnostic criteria. We also confirm that the mTOR pathway is strongly implicated in the pathogenesis of this tumor mainly through MTOR, TCS1, and TSC2 mutations, but other genes could also be involved in the pathway activation, especially in LOTs without “canonical” mutations.
- Open Access
- 1 October 2022
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 11 (10) , 1458-1465
A case report of myoid gonadal stromal tumor treated with testis sparing surgery
Case Report A case of myoid gonadal stromal tumor treated with testis sparing surgery Amelio Ercolino, Francesco Manes, Francesco Vasuri, Lorenzo Bianchi, Marco Garofalo, Pietro Piazza, Beniamino Corcioni, Riccardo Schiavina, Rita Golfieri, Michelangelo Fiorentino, Maurizio Colecchia, Eugenio Brunocilla
- 1 October 2022
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 11 (10) , 1458-1465
Open AccessA case report of myoid gonadal stromal tumor treated with testis sparing surgery
Case Report A case of myoid gonadal stromal tumor treated with testis sparing surgery Amelio Ercolino, Francesco Manes, Francesco Vasuri, Lorenzo Bianchi, Marco Garofalo, Pietro Piazza, Beniamino Corcioni, Riccardo Schiavina, Rita Golfieri, Michelangelo Fiorentino, Maurizio Colecchia, Eugenio Brunocilla
- 25 November 2021
- Published by Springer Nature in International Urology and Nephrology
- Vol. 54 (2) , 263-271
Evaluating the performance of clinical and radiological data in predicting prostate cancer in prostate imaging reporting and data system version 2.1 category 3 lesions of the peripheral and the transition zones
Purpose To define the value of clinical and radiological data, using multiparametric magnetic resonance imaging (mpMRI), to predict prostate cancer (PCa) in prostate imaging reporting and data system version 2.1 (PIRADSv2.1) 3 lesions of the peripheral and the transition zones (PZ and TZ). Methods The mpMRI of patients with PIRADSv2.1 3 lesions who had undergone fusion targeted biopsy was reviewed. Morphological pattern, diffusion parameters and vascularisation were evaluated. The radiological/histopathological data of benign and malignant lesions, between the PZ and TZ were compared. Univariate and multivariate analyses were carried out to identify the clinical and radiological data capable of predicting PCa. Results One hundred and twenty-three lesions were assessed, 93 (76%) in the PZ and 30 (24%) in the TZ. Of these, 56 (46%) were PCa and 67 (54%) were benign. The majority of the PCas were Grade Group System (GGS) 1 (38%) and GGS 2 (39%); tumours having a GGS ≥ 3 were more frequently in the TZ (p = 0.02). Univariate analysis showed a significant correlation between PCa and prostate volume, prostate-specific antigen (PSA) density, lesion zone and the apparent diffusion coefficient. At multivariate logistic regression PSA density > 0.15 ng/ml/ml {Odds ratio [OR] 2.38; p = 0.001} and lesion zone (i.e. TZ OR 7.55) were independent predictors of PCa (all p ≤ 0.04). Conclusion In solitary PIRADSv2.1 3 lesions, the most important predictive factor was the location zone, with a much greater risk for TZ lesions.
- 25 November 2021
- Published by Springer Nature in International Urology and Nephrology
- Vol. 54 (2) , 263-271
Evaluating the performance of clinical and radiological data in predicting prostate cancer in prostate imaging reporting and data system version 2.1 category 3 lesions of the peripheral and the transition zones
Purpose To define the value of clinical and radiological data, using multiparametric magnetic resonance imaging (mpMRI), to predict prostate cancer (PCa) in prostate imaging reporting and data system version 2.1 (PIRADSv2.1) 3 lesions of the peripheral and the transition zones (PZ and TZ). Methods The mpMRI of patients with PIRADSv2.1 3 lesions who had undergone fusion targeted biopsy was reviewed. Morphological pattern, diffusion parameters and vascularisation were evaluated. The radiological/histopathological data of benign and malignant lesions, between the PZ and TZ were compared. Univariate and multivariate analyses were carried out to identify the clinical and radiological data capable of predicting PCa. Results One hundred and twenty-three lesions were assessed, 93 (76%) in the PZ and 30 (24%) in the TZ. Of these, 56 (46%) were PCa and 67 (54%) were benign. The majority of the PCas were Grade Group System (GGS) 1 (38%) and GGS 2 (39%); tumours having a GGS ≥ 3 were more frequently in the TZ (p = 0.02). Univariate analysis showed a significant correlation between PCa and prostate volume, prostate-specific antigen (PSA) density, lesion zone and the apparent diffusion coefficient. At multivariate logistic regression PSA density > 0.15 ng/ml/ml {Odds ratio [OR] 2.38; p = 0.001} and lesion zone (i.e. TZ OR 7.55) were independent predictors of PCa (all p ≤ 0.04). Conclusion In solitary PIRADSv2.1 3 lesions, the most important predictive factor was the location zone, with a much greater risk for TZ lesions.
- 1 July 2021
- Published by Edizioni Minerva Medica in Minerva Urology and Nephrology
- Vol. 73 (3) , 357-366
Diagnostic performance of MRI/TRUS fusion-guided biopsies vs. systematic prostate biopsies in biopsy-naïve, previous negative biopsy patients and men undergoing active surveillance
Article: Diagnostic performance of MRI/TRUS fusion-guided biopsies vs. systematic prostate biopsies in biopsy-naïve, previous negative biopsy patients and men undergoing active surveillance - Minerva Urology and Nephrology 2021 June;73(3):357-66 - Minerva Medica - Journals
- 1 July 2021
- Published by Edizioni Minerva Medica in Minerva Urology and Nephrology
- Vol. 73 (3) , 357-366
Diagnostic performance of MRI/TRUS fusion-guided biopsies vs. systematic prostate biopsies in biopsy-naïve, previous negative biopsy patients and men undergoing active surveillance
Article: Diagnostic performance of MRI/TRUS fusion-guided biopsies vs. systematic prostate biopsies in biopsy-naïve, previous negative biopsy patients and men undergoing active surveillance - Minerva Urology and Nephrology 2021 June;73(3):357-66 - Minerva Medica - Journals
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S1799
The use of augmented reality to guide intraoperative frozen section during robot-assisted radical prostatectomy
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S1799
The use of augmented reality to guide intraoperative frozen section during robot-assisted radical prostatectomy
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S110
Comparison of two techniques for Holmium Laser Enucleation of Prostate (HoLEP): Long-term outcomes and predictive model for symptoms recurrence
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S110
Comparison of two techniques for Holmium Laser Enucleation of Prostate (HoLEP): Long-term outcomes and predictive model for symptoms recurrence
- Open Access
- 17 May 2021
- Published by Wiley in International Journal of Urology
- Vol. 28 (8) , 875
Re: Three‐dimensional‐printed soft kidney model for surgical simulation of robot‐assisted partial nephrectomy: A proof‐of‐concept study
- 17 May 2021
- Published by Wiley in International Journal of Urology
- Vol. 28 (8) , 875
Open AccessRe: Three‐dimensional‐printed soft kidney model for surgical simulation of robot‐assisted partial nephrectomy: A proof‐of‐concept study
- 1 March 2021
- Published by Elsevier in Pathology - Research and Practice
- Vol. 219, 153350
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing
- 1 March 2021
- Published by Elsevier in Pathology - Research and Practice
- Vol. 219, 153350
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing
- 1 August 2020
- Published by Elsevier in Pathology - Research and Practice
- Vol. 216 (8) , 153012
Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer
- 1 August 2020
- Published by Elsevier in Pathology - Research and Practice
- Vol. 216 (8) , 153012
Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer